Novartis gets U.S. approval for new drug to treat multiple sclerosis
Novartis AG won U.S. Food and Drug Administration approval for its new multiple sclerosis drug Mayzent, as the Swiss drugmaker seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Brain | Food and Drug Administration (FDA) | Health | Multiple Sclerosis | Neurology | Switzerland Health